Difference between revisions of "Doxorubicin (Adriamycin)"
Jump to navigation
Jump to search
m (Text replace - "or the prescribing information<ref name="insert"></ref>." to "or the prescribing information.<ref name="insert"></ref>") |
(updated content) |
||
| Line 1: | Line 1: | ||
| − | Also known as hydroxydaunorubicin. | + | Also known as hydroxydaunorubicin or Rubex. |
==General information== | ==General information== | ||
| − | Class/mechanism: Anthracycline; binds and intercalates into DNA, inhibiting nucleotide replication and DNA/RNA polymerase activity. Intercalation of DNA triggers DNA cleavage via topoisomerase II. Toxic effects on organs may be related to cell membrane lipid binding activities; enzymatic electron reduction of doxorubicin creates reactive species, e.g. hydroxyl free radicals OH-, which has been implicated in cardiotoxicity by means of Cu (II) and Fe (III) reduction.<ref name="insert">[http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Ben+Venue_Bedford+Labs/55390-237-01+ADR+50MG/5539023701 Doxorubicin (Adriamycin) package insert]</ref><ref>[ | + | Class/mechanism: Anthracycline; binds and intercalates into DNA, inhibiting nucleotide replication and DNA/RNA polymerase activity. Intercalation of DNA triggers DNA cleavage via topoisomerase II. Toxic effects on organs may be related to cell membrane lipid binding activities; enzymatic electron reduction of doxorubicin creates reactive species, e.g. hydroxyl free radicals OH-, which has been implicated in cardiotoxicity by means of Cu (II) and Fe (III) reduction.<ref name="insert">[http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Ben+Venue_Bedford+Labs/55390-237-01+ADR+50MG/5539023701 Doxorubicin (Adriamycin) package insert]</ref><ref>[[Media:Doxorubicin.pdf | Doxorubicin (Adriamycin) package insert (locally hosted backup)]]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: [[vesicant]] | <br>Extravasation: [[vesicant]] | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Acute lymphocytic leukemia]] | ||
| + | *[[Basal cell and squamous cell skin cancer]] | ||
| + | *[[Bladder cancer]] | ||
| + | *[[Bone cancer]] | ||
| + | *[[Breast cancer]] | ||
| + | *[[Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)]] | ||
| + | *[[Hepatobiliary cancer]] | ||
| + | *[[Hodgkin lymphoma]] | ||
| + | *[[Multiple myeloma]] | ||
| + | *[[Non-Hodgkin lymphoma]] | ||
| + | *[[Renal cancer]] | ||
| + | *[[Thymoma]] | ||
| + | *[[Uterine cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://chemocare.com/ | + | *[http://chemocare.com/chemotherapy/drug-info/doxorubicin.aspx Doxorubicin (Adriamycin) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/doxorubicin.aspx Doxorubicin (Adriamycin) patient drug information (Chemocare)]</ref> |
| + | *[http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Ben+Venue_Bedford+Labs/55390-237-01+ADR+50MG/5539023701 Doxorubicin (Adriamycin) package insert page 1]<ref name="insert"></ref> | ||
*[http://www.uptodate.com/contents/doxorubicin-patient-drug-information Doxorubicin (Adriamycin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/doxorubicin-patient-drug-information Doxorubicin (Adriamycin) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/doxorubicin-patient-drug-information Doxorubicin (Adriamycin) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/doxorubicin-patient-drug-information Doxorubicin (Adriamycin) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Anthracyclines]] | ||
| + | [[Category:Topoisomerase inhibitors]] | ||
| + | [[Category:Vesicant chemotherapy]] | ||
| + | [[Category:Acute lymphocytic leukemia medications]] | ||
| + | [[Category:Basal cell and squamous cell skin cancer medications]] | ||
| + | [[Category:Bladder cancer medications]] | ||
| + | [[Category:Bone cancer medications]] | ||
| + | [[Category:Breast cancer medications]] | ||
| + | [[Category:Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications]] | ||
| + | [[Category:Hepatobiliary cancer medications]] | ||
| + | [[Category:Hodgkin lymphoma medications]] | ||
| + | [[Category:Multiple myeloma medications]] | ||
| + | [[Category:Non-Hodgkin lymphoma medications]] | ||
| + | [[Category:Renal cancer medications]] | ||
| + | [[Category:Thymoma medications]] | ||
| + | [[Category:Uterine cancer medications]] | ||
Revision as of 04:44, 15 October 2012
Also known as hydroxydaunorubicin or Rubex.
General information
Class/mechanism: Anthracycline; binds and intercalates into DNA, inhibiting nucleotide replication and DNA/RNA polymerase activity. Intercalation of DNA triggers DNA cleavage via topoisomerase II. Toxic effects on organs may be related to cell membrane lipid binding activities; enzymatic electron reduction of doxorubicin creates reactive species, e.g. hydroxyl free radicals OH-, which has been implicated in cardiotoxicity by means of Cu (II) and Fe (III) reduction.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Acute lymphocytic leukemia
- Basal cell and squamous cell skin cancer
- Bladder cancer
- Bone cancer
- Breast cancer
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)
- Hepatobiliary cancer
- Hodgkin lymphoma
- Multiple myeloma
- Non-Hodgkin lymphoma
- Renal cancer
- Thymoma
- Uterine cancer
Patient drug information
- Doxorubicin (Adriamycin) patient drug information (Chemocare)[3]
- Doxorubicin (Adriamycin) package insert page 1[1]
- Doxorubicin (Adriamycin) patient drug information (UpToDate)[4]
References
Categories:
- Drug index
- Chemotherapy
- Anthracyclines
- Topoisomerase inhibitors
- Vesicant chemotherapy
- Acute lymphocytic leukemia medications
- Basal cell and squamous cell skin cancer medications
- Bladder cancer medications
- Bone cancer medications
- Breast cancer medications
- Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL) medications
- Hepatobiliary cancer medications
- Hodgkin lymphoma medications
- Multiple myeloma medications
- Non-Hodgkin lymphoma medications
- Renal cancer medications
- Thymoma medications
- Uterine cancer medications